journal article·2026-06Open access

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong

Advanced Science· Volume 13· Issue 32

Abstract

ABSTRACT Aberrant DNA methylation and consequent silencing of tumor suppressor gene (TSGs) are maintained by UHRF1‐mediated recruitment of DNMT1, making the UHRF1‐DNMT1 axis as an attractive target for hypomethylating agents (HMAs). However, fully reversing DNA methylation abnormalities requires lowering DNMT1 below a deep threshold, posing major drug discovery challenges. Here, we demonstrated that a similarly stringent threshold applied to UHRF1 in maintaining hypermethylated TSG suppression. Genetically reducing redundancy in DNMT1 or UHRF1 markedly lowered these thresholds, sensitizing cells to their inhibition. These findings were translated into engineered recombinant reporter systems tied to endogenous hypermethylated promoters in hypomorphic cells, substantially improving sensitivity and dynamic range for monitoring HMA‐induced TSG reactivation. Pilot high‐throughput screening validated assay robustness and specificity for DNMT1 and UHRF1 inhibitors. Additionally, these platforms enabled optimization of timing and combination strategies pairing DNMT1/UHRF1 inhibitors with other epigenetic agents to maximize TSG re‐expression. Our study supports the concept of maintenance methylation thresholds and provides versatile tools for discovering novel HMAs and designing epigenetic combination therapies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Epigenetics and DNA Methylation · Cancer-related gene regulation · Autophagy in Disease and Therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Life Sciences and Medicine University of Science and Technology of China Hefei China

Institute of Drug Discovery Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine China‐New Zealand Joint Laboratory on Biomedicine and Health Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences Guangzhou China

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The Johns Hopkins University School of Medicine Baltimore Maryland USA

College of Pharmacy Basic Medicine Research and Innovation Center For Novel Target and Therapeutic Intervention (Ministry of Education) Department of Breast and Thyroid Surgery of the Second Affiliated Hospital Chongqing Medical University Chongqing China

Department of Epigenetics Van Andel Institute Grand Rapids Michigan USA

Funding

National Natural Science Foundation of China

References (100+)

Show source-provided references
1. 10.1158/2159‐8290.Cd‐24‐029610.1158/2159‐8290.Cd‐24‐0296 ↗
2. 10.1101/cshperspect.a01950510.1101/cshperspect.a019505 ↗
3. 10.1007/978‐3‐319‐43624‐1_710.1007/978‐3‐319‐43624‐1_7 ↗
4. 10.1038/s41467‐024‐45605‐410.1038/s41467‐024‐45605‐4 ↗
5. 10.1016/0022‐2836(88)90122‐210.1016/0022‐2836(88)90122‐2 ↗
6. 10.1101/gr.208108.11610.1101/gr.208108.116 ↗
7. 10.1038/nature0639710.1038/nature06397 ↗
8. 10.1126/science.114793910.1126/science.1147939 ↗
9. 10.1016/j.ccr.2011.12.02910.1016/j.ccr.2011.12.029 ↗
10. 10.1038/s43018‐021‐00249‐x10.1038/s43018‐021‐00249‐x ↗
11. 10.1016/j.ccell.2019.03.00310.1016/j.ccell.2019.03.003 ↗
12. 10.1038/s41467‐024‐55481‐710.1038/s41467‐024‐55481‐7 ↗
13. 10.1101/cshperspect.a04163710.1101/cshperspect.a041637 ↗
14. 10.1182/blood‐2006‐05‐02116210.1182/blood‐2006‐05‐021162 ↗
15. 10.1056/NEJMoa201297110.1056/NEJMoa2012971 ↗
16. 10.1182/blood.202402721710.1182/blood.2024027217 ↗
17. 10.1038/s43018‐024‐00777‐210.1038/s43018‐024‐00777‐2 ↗
18. 10.1038/s44318‐024‐00108‐210.1038/s44318‐024‐00108‐2 ↗
19. 10.15252/embj.201910149610.15252/embj.2019101496 ↗
20. 10.1038/s44319‐025‐00385‐w10.1038/s44319‐025‐00385‐w ↗
21. 10.1038/ncponc035510.1038/ncponc0355 ↗
22. 10.1177/247255521876627810.1177/2472555218766278 ↗
23. 10.1038/s41598‐020‐80588‐410.1038/s41598‐020‐80588‐4 ↗
24. 10.1074/jbc.M112.44389510.1074/jbc.M112.443895 ↗
25. 10.1093/nar/gkab98910.1093/nar/gkab989 ↗
26. 10.1016/j.ab.2010.02.03210.1016/j.ab.2010.02.032 ↗
27. 10.1016/j.bios.2018.10.05410.1016/j.bios.2018.10.054 ↗
28. 10.1101/gad.146370610.1101/gad.1463706 ↗
29. 10.1038/nature0443110.1038/nature04431 ↗
30. 10.1016/j.bbrc.2010.08.04810.1016/j.bbrc.2010.08.048 ↗
31. 10.4161/epi.2619510.4161/epi.26195 ↗
32. 10.1134/s002689332104009910.1134/s0026893321040099 ↗
33. 10.1158/0008‐5472.Can‐13‐228710.1158/0008‐5472.Can‐13‐2287 ↗
34. 10.1016/j.cell.2015.08.04610.1016/j.cell.2015.08.046 ↗
35. 10.1186/1423‐0127‐18‐310.1186/1423‐0127‐18‐3 ↗
36. 10.1158/0008‐5472.Can‐09‐447410.1158/0008‐5472.Can‐09‐4474 ↗
37. 10.1016/j.mrfmmm.2004.08.01110.1016/j.mrfmmm.2004.08.011 ↗
38. 10.1080/15592294.2016.126788710.1080/15592294.2016.1267887 ↗
39. 10.1038/3501000010.1038/35010000 ↗
40. 10.1073/pnas.060460210310.1073/pnas.0604602103 ↗
41. 10.1083/jcb.20061006210.1083/jcb.200610062 ↗
42. 10.3324/haematol.2020.24865810.3324/haematol.2020.248658 ↗
43. 10.1186/s13072‐021‐00429‐010.1186/s13072‐021‐00429‐0 ↗
44. 10.1038/nprot.2007.40810.1038/nprot.2007.408 ↗
45. 10.1021/cb300247810.1021/cb3002478 ↗
46. 10.1038/ng133010.1038/ng1330 ↗
47. 10.1126/science.107254510.1126/science.1072545 ↗
48. 10.1126/science.110165910.1126/science.1101659 ↗
49. 10.1016/j.celrep.2015.03.03810.1016/j.celrep.2015.03.038 ↗
50. 10.1128/mcb.23.23.8429‐8439.200310.1128/mcb.23.23.8429‐8439.2003 ↗
51. 10.1016/j.cell.2005.08.01110.1016/j.cell.2005.08.011 ↗
52. 10.1016/j.ccr.2004.08.03010.1016/j.ccr.2004.08.030 ↗
53. 10.1093/nar/gkae110510.1093/nar/gkae1105 ↗
54. 10.1101/gad.220467.11310.1101/gad.220467.113 ↗
55. 10.1038/s41467‐024‐47314‐410.1038/s41467‐024‐47314‐4 ↗
56. 10.1126/sciimmunol.adm825110.1126/sciimmunol.adm8251 ↗
57. 10.1021/acschembio.7b0089010.1021/acschembio.7b00890 ↗
58. 10.1016/j.molcel.2024.11.00910.1016/j.molcel.2024.11.009 ↗
59. 10.1038/s41467‐020‐15006‐410.1038/s41467‐020‐15006‐4 ↗
60. 10.1074/jbc.RA119.00800810.1074/jbc.RA119.008008 ↗
61. 10.1038/s41586‐018‐0751‐510.1038/s41586‐018‐0751‐5 ↗
62. 10.1038/s41467‐020‐19603‐110.1038/s41467‐020‐19603‐1 ↗
63. 10.1177/10870571990040020610.1177/108705719900400206 ↗
64. 10.1038/aps.2017.5910.1038/aps.2017.59 ↗
65. 10.1021/acs.jnatprod.4c0145810.1021/acs.jnatprod.4c01458 ↗
66. Acetyldinaline: A New Oral Cytostatic Drug With Impressive Differential Activity Against Leukemic Cells and Normal Stem Cells–Preclinical Studies in a Relevant Rat Model for Human Acute Myelocytic Leukemia
67. 10.1021/jm701079h10.1021/jm701079h ↗
68. 10.1073/pnas.130380011010.1073/pnas.1303800110 ↗
69. 10.1021/acsmedchemlett.5b0003710.1021/acsmedchemlett.5b00037 ↗
70. 10.1021/acs.jmedchem.6b0051510.1021/acs.jmedchem.6b00515 ↗
71. 10.1021/acs.jmedchem.1c0214810.1021/acs.jmedchem.1c02148 ↗
72. 10.1158/1535‐7163.Mct‐07‐202610.1158/1535‐7163.Mct‐07‐2026 ↗
73. 10.1371/journal.pgen.003015710.1371/journal.pgen.0030157 ↗
74. 10.1158/0008‐5472.Can‐06‐202910.1158/0008‐5472.Can‐06‐2029 ↗
75. 10.1016/j.canlet.2022.21589910.1016/j.canlet.2022.215899 ↗
76. 10.1158/2159‐8290.Cd‐21‐167110.1158/2159‐8290.Cd‐21‐1671 ↗
77. 10.1182/bloodadvances.202200836210.1182/bloodadvances.2022008362 ↗
78. 10.1021/acs.jmedchem.4c0131010.1021/acs.jmedchem.4c01310 ↗
79. 10.1016/j.cell.2017.10.02210.1016/j.cell.2017.10.022 ↗
80. 10.1038/7712410.1038/77124 ↗
81. 10.1038/7702310.1038/77023 ↗
82. 10.1038/s41586‐020‐2054‐x10.1038/s41586‐020‐2054‐x ↗
83. 10.1126/sciadv.adk442310.1126/sciadv.adk4423 ↗
84. 10.1158/0008‐5472.Can‐20‐424310.1158/0008‐5472.Can‐20‐4243 ↗
85. 10.1038/s41571‐019‐0266‐510.1038/s41571‐019‐0266‐5 ↗
86. 10.1056/NEJMra180503510.1056/NEJMra1805035 ↗
87. 10.1038/s41573‐020‐0077‐510.1038/s41573‐020‐0077‐5 ↗
88. 10.1016/j.tig.2021.05.00210.1016/j.tig.2021.05.002 ↗
89. 10.1038/s41392‐023‐01342‐610.1038/s41392‐023‐01342‐6 ↗
90. 10.1038/s41422‐021‐00565‐y10.1038/s41422‐021‐00565‐y ↗
91. 10.1093/nar/gks03110.1093/nar/gks031 ↗
92. 10.1016/j.ccell.2017.04.00510.1016/j.ccell.2017.04.005 ↗
93. 10.1016/j.molcel.2025.04.01910.1016/j.molcel.2025.04.019 ↗
94. 10.1158/0008‐5472.Can‐08‐070010.1158/0008‐5472.Can‐08‐0700 ↗
95. 10.1016/j.molcel.2020.01.01710.1016/j.molcel.2020.01.017 ↗
96. 10.1093/narcan/zcad02210.1093/narcan/zcad022 ↗
97. Characteristics of Mouse Leukemic Cells Resistant to 5‐azacytidine and 5‐aza‐2'‐deoxycytidine
98. 10.1038/s41375‐020‐1003‐x10.1038/s41375‐020‐1003‐x ↗
99. 10.1172/jci7878910.1172/jci78789 ↗
100. 10.1038/ncomms1246410.1038/ncomms12464 ↗